Tony Huge calls this one of the more important videos he has made. The claim is simple: the BPC-157 peptide has been in the published literature since 1993, has more than 300 peer-reviewed studies behind it, and your doctor has probably never read one, and since 2022 could not easily prescribe it even if he had. Tony walks the origin story, the four mechanisms the research describes, the compounding decision that pulled it out of regulated pharmacies, and the economics he says explain the whole thing. He also says, in his own words, where the human evidence runs out.
Video: BPC-157: Your Doctor Knows About This Peptide, He’s Just Not Allowed To Prescribe It. Published July 17, 2026. Watch on YouTube.
What the video covers
- 00:00 The hook: A compound with a 20-year track record in the literature that clinicians cannot discuss without liability risk.
- 01:30 The problem: Tens of millions of people with tendon, ligament, nerve and gut conditions being told recovery just takes time.
- 03:00 The backstory: A 1993 gastric juice research program, a 15-amino-acid peptide, and the severed-tendon rat model.
- 05:30 The science: Four mechanisms: VEGF and angiogenesis, nitric oxide modulation, gastrointestinal repair, neuroprotection.
- 09:30 What the research found: Injectable and oral forms, microgram-scale doses in the animal work, and the research-compound status.
- 11:30 The controversy: The 2022 FDA compounding guidance, the patent gap, and the NSAID comparison.
- 13:30 The close: What Tony thinks the knowledge gap costs people, and what he says the next step is.
Why the stomach does not digest itself
The origin story Tony tells begins with a puzzle physiologists chased for decades: the stomach is bathed in acid strong enough to dissolve metal, yet under normal conditions it almost never ulcerates. A university research team studying gastric juice in the early 1990s found part of the answer in a family of protective peptides. One of them, isolated and synthesized in a stable form, did something no other compound they had tested could replicate. It healed tissue fast, across several organ systems at once. BPC stands for body protection compound. It is a 15-amino-acid peptide the stomach produces naturally in small amounts.
The model that made its name was the severed Achilles tendon in rats, a complete tear that in humans means surgical reconstruction and up to a year of rehab. Tony reports that treated animals showed significantly greater tendon strength and structural integrity within three weeks while the untreated group was still severely impaired. The work then spread to intestinal damage, nerve injury, skin wounds, cardiac tissue, liver and the central nervous system, with the same pattern each time: faster healing, less inflammation, accelerated regeneration. By the early 2000s, he says, researchers in gastroenterology, orthopedics, neurology and cardiology were independently publishing on the same molecule, which almost never happens.
Four mechanisms, one theme
The first is angiogenesis. No blood flow, no healing, and Tony cites research describing BPC-157 as one of the most potent up-regulators of VEGF, the body’s own signal to grow new blood vessels into injured tissue, ever documented in a non-pharmaceutical compound. More vessels means more oxygen, more oxygen means more collagen synthesis, and more collagen means tissue that repairs rather than scars.
The second is nitric oxide modulation, and this is where Tony draws the line that matters most to him. In injured tissue the nitric oxide system dysregulates, producing too much inflammation for too long. What the research describes is normalization, not suppression: the destructive phase shortens and the regenerative phase extends. He contrasts that with common NSAIDs, which multiple studies show can delay tendon and bone repair by blocking the early inflammatory signal the rebuild needs. Ibuprofen puts out the fire that starts the repair. BPC-157, in the research he cites, regulates the fire.
“It doesn’t eliminate inflammation. Inflammation is required as part of the healing process. It brings it back into a regulated, productive state.”
Tony Huge, 07:10
The third is gastrointestinal repair, which he calls the most dramatic area in the research. Standard care for inflammatory bowel conditions leans on immunosuppressants with serious known risks. In controlled animal studies, Tony reports, BPC-157 reversed inflammatory bowel lesions that were essentially irreversible under current standards, and did it without suppressing the immune system. The fourth is neuroprotection: models of traumatic brain injury, stroke and nerve transection, with documented neuroprotective and regenerative effects and proposed applications in dopaminergic pathway repair. One compound, four systems, which is exactly why he finds the silence around it hard to accept.
What the studies used, and what they are
Two forms appear in the literature. The injectable, subcutaneous form has the largest body of research. The oral form shows particular relevance in gut studies, where local action appears to matter. What strikes Tony about the published doses is how small they are: microgram quantities, scaled from animal models to human body weight by standard conversion, minuscule next to virtually any conventional drug. Published cycles range from short acute protocols to longer chronic administration, without the toxicity signals that normally halt a compound at this stage.
He is explicit about status. BPC-157 is a research compound. It is not FDA-approved and not a licensed medication. He is not telling anyone what to take. His stated job is to bring the research to people whose doctors do not have time to read it, and his stated next step for anyone it applies to is a physician who reads the literature, because those clinicians exist.
The 2022 decision and the money behind it
In 2022 the FDA issued guidance that effectively removed BPC-157, along with other peptides, from the category of substances licensed compounding pharmacies could produce. Regulated pharmacies that had been supplying it under physician supervision were told to stop. The stated reason was that it had not completed the full drug approval process. Tony grants that this is technically accurate and calls it profoundly misleading.
His reasoning is the patent argument. Approval costs one to three billion dollars and takes 10 to 15 years, carried entirely by companies, and companies only pursue it for compounds they can patent and sell at a profit. A naturally occurring peptide cannot easily be patented, so nobody has a reason to fund the trials. The approval system was never designed to evaluate compounds that cannot generate profit, and BPC-157, in his view, is the clearest example of one that falls through that gap. He balances that with the FDA’s side: its mandate is safety, and the honest answer is that large randomized placebo-controlled human trials do not yet exist. Then he sets the other column: over 300 animal studies, decades of documented use with near-zero serious adverse event records, against over-the-counter NSAIDs that he says contribute to an estimated 16,000 deaths a year from gastrointestinal complications alone.
Cheat Sheet Pivot
What Tony reported and what the cited research describes, not instructions.
- The compound: a 15-amino-acid peptide isolated from gastric juice in the early 1990s, with over 300 peer-reviewed studies, overwhelmingly in animals.
- The four documented mechanisms: VEGF-driven angiogenesis, nitric oxide normalization, reversal of inflammatory bowel lesions in animal models, and neuroprotection in brain and nerve injury models.
- Published research used microgram-scale doses, in injectable form for most tissue work and oral form for gut work.
- The 2022 FDA compounding guidance is why regulated pharmacies stopped supplying it; Tony attributes the missing trials to patent economics, not to a safety finding.
- His comparison point for safety is the NSAID class, which is approved, freely sold, and in his figures kills thousands a year through gastrointestinal complications.
BPC-157 sits alongside the other healing peptides in the Miracle Molecules Cheat Sheet. For Tony’s own long-run experience with the compound, read BPC-157 Complete Protocol Guide: My 9-Year Real-World Experience, and for a more skeptical walk through the same literature, see BPC-157 Explained: Rat Studies, Human Data and Trade-Offs.
Where the evidence stops
Nearly everything in this video comes from animal models. The severed tendon, the bowel lesions, the brain injury work, the safety record: rats, not randomized humans. Tony says the large human trials do not exist and does not pretend otherwise. The 16,000 NSAID deaths figure is an estimate he cites, not something the video sources on screen. The “your doctor is not allowed” framing is his characterization of liability risk after the 2022 guidance, not a legal prohibition on discussion.
It is worth reading this video next to Tony’s own piece on the patent gap, where he warns that “unfunded” is not the same as “suppressed.” This video leans harder into the second framing than that one does, and the two together are the honest picture: a compound with a strong animal record, thin human data, and no commercial reason for anyone to close that gap.
Keep going
For the regulatory backstory, read The FDA Peptide Crackdown: Regulatory Capture, Not Patient Safety. Companion write-ups reach the tonyhuge.is email list first, and the peptide archive is on tonyhuge.is.